IPD Archives

Publications

Vivli aims to advance human health through clinical research data sharing. One of the key ways we support this is through the Vivli platform, which facilitates data sharing for research teams working on a range of topics. These tables provide details of approved research proposals that have published or presented their results.

Top publications by PubMed citations

Year	Data Request ID	Lead Investigator	Institution	Research Proposal Title	Publication	Data Contributor(s)	PubMed Citation Total
2023	6104	Pratik Sinha	Washington University	Heterogeneous treatment effects in molecular phenotypes of sepsis	Sinha, P., Kerchberger, V.E., Willmore, A., Chambers, J., Zhuo, H., Abbott, J., Jones, C., Wickersham, N., Wu, N., Neyton, L. and Langelier, C.R., 2023. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. The Lancet Respiratory Medicine. Doi:10.1016/S2213-2600(23)00237-0	Lilly	101
2021	5096	Joo Sang Lee	Samsung Medical Center, South Korea	Harnessing genetic interactions to advance precision cancer medicine	Synthetic lethality-mediated precision oncology via the tumor transcriptome. Lee, Joo Sang et al. Cell, Volume 184, Issue 9, 2487 - 2502.e13. doi: 10.1016/j.cell.2021.03.030	Tempus AI, Inc.	92
2023	4113	Lesley Inker	Tufts Medical Center	Chronic Kidney Disease Epidemiology - Clinical Trials Consortium (CKD-EPI CT)	Inker, L.A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G.B., Badve, S.V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J. and Goicoechea, M., 2023. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, pp.1-10. Doi: 10.1038/s41591-023-02418-0	GlaxoSmithKline, Takeda	80
2023	7875	Marco Valgimigli	Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI)	P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative)	Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen Alf-Age, Zhao Q, Woodward M, Chiarito M, McFadden EP, Valgimigli M. PANTHER. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. Journal of the American College of Cardiology. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051	Sanofi	65
2020	4540	Chris Gale	University of Leeds	Efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trial	Wilkinson, C., Wu, J., Searle, S.D. et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med 18, 401 (2020). doi: 10.1186/s12916-020-01870-w	Daiichi Sankyo	62
2020	4116	Sharon Straus	St. Michael's Hospital	Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis	Veroniki AA, Ashoor H, Rios P, Seitidis G, Mavridis D, Holroyd-Leduc J, Straus S, Tricco A. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: An individual patient data network meta-analysis. In: Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews 2020;(9 Suppl 1):455. doi: 10.1002/14651858.CD202001	AbbVie	60
2022	4116	Sharon Strauss	St. Michael’s Hospital	Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis	Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia: a systematic review with individual patient data network meta-analysis BMJ Open 2022;12:e053012. doi: 10.1136/bmjopen-2021-053012	AbbVie	60
2022	7074	Gregory YH Lip	University of Liverpool	Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes	Romiti GF, Proietti M, Bonini N, Ding WY, Boriani G, Huisman MV, Lip GYH; GLORIA-AF Investigators. Clinical Complexity Domains, Anticoagulation, and Outcomes in Patients with Atrial Fibrillation: A Report from the GLORIA-AF Registry Phase II and III. Thromb Haemost. 2022 Aug 29. doi: 10.1055/s-0042-1756355	Boehringer Ingelheim	60
2020	5895, 6117	Ashley Hopkins	Flinders University	Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers	Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, Andrew Rowland and Michael J. Sorich. Clin Cancer Res October 15 2020 (26) (20) 5487-5493; doi: 10.1158/1078-0432.CCR-20-1876	Roche	57
2022	4329	Shomron Ben-Horin	Sun Yatsen 1st affiliated Hospital	Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease	Shomron Ben-Horin, Lena Novack, Ren Mao, Jing Guo, Yue Zhao, Ruslan Sergienko, Jian Zhang, Taku Kobayashi, Toshifumi Hibi, Yehuda Chowers, Laurent Peyrin-Biroulet, Jean Frederic Colombel, Gilaad G. Kaplan, Min-hu Chen. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology, 2021, ISSN 0016-5085. doi: 10.1053/j.gastro.2021.10.037	AbbVie, Biogen, Johnson & Johnson, Takeda, UCB	57

Top publications by Altmetrics score

Year	Data Request ID	Lead Investigator	Institution	Research Proposal Title	Publication	Data Contributor(s)	PubMed Citation Total
2025	9813	Sameer Jauhar	King's College London	Conducting a systematic review and meta-analysis to assess the incidence and severity of withdrawal symptoms following discontinuation of antidepressants	Kalfas, Michail, Tsapekos, Dimosthenis, Butler, Matthew, McCutcheon, Robert A., Pillinger, Toby, Strawbridge, Rebecca, Bhat, Bhagyashree Bhaskar, Haddad, Peter M., Cowen, Philip J., Howes, Oliver D., Joyce, Dan W., Nutt, David J., Baldwin, David S., Pariante, Carmine M., Lewis, Gemma, Young, Allan H., Lewis, Glyn, Hayes, Joseph F. and Jauhar, Sameer. "Incidence and Nature of Antidepressant Discontinuation Symptoms." JAMA Psychiatryvol. , no. , Jul. 2025, pp. https://doi.org/10.1001/jamapsychiatry.2025.1362	Lilly, Lundbeck, Pfizer, Takeda	N/A
2023	6544	Angela Wu	University of Oxford	Investigating the association between smoking cessation and mental health in people with and without psychiatric disorders	Wu, A.D., Gao, M., Aveyard, P. and Taylor, G., 2023. Smoking Cessation and Changes in Anxiety and Depression in Adults With and Without Psychiatric Disorders. JAMA Network Open, 6(5), pp.e2316111-e2316111. Doi: 10.1001/jamanetworkopen.2023.16111	Pfizer	17
2025	5959	John Dennis	University of Exeter Medical School	Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes	Dennis, J.M., Young, K.G., Cardoso, P., Güdemann, L.M., McGovern, A.P., Farmer, A., Holman, R.R., Sattar, N., McKinley, T.J., Pearson, E.R. and Jones, A.G., 2025. A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study. The Lancet. Doi: 10.1016/S0140-6736(24)02617-5	Boehringer Ingelheim, Takeda	N/A
2025	7810	Diego Chowell	Icahn School of Medicine at Mount Sinai	Machine learning model to predict cancer immunotherapy response	Yoo, S.K., Fitzgerald, C.W., Cho, B.A., Fitzgerald, B.G., Han, C., Koh, E.S., Pandey, A., Sfreddo, H., Crowley, F., Korostin, M.R. and Debnath, N., 2025. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nature Medicine, pp.1-12. Doi: 10.1038/s41591-024-03398-5	Roche	N/A
2023	7875	Marco Valgimigli	Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI)	P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative)	Gragnano F, Cao D, Pirondini L, Franzone A, Kim HS, von Scheidt M, Pettersen Alf-Age, Zhao Q, Woodward M, Chiarito M, McFadden EP, Valgimigli M. PANTHER. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. Journal of the American College of Cardiology. 2023 Jul 11;82(2):89-105. doi: 10.1016/j.jacc.2023.04.051	Sanofi	51
2025	9492, 8697	David McAllister	University of Glasgow	Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions	Hanlon P., Butterly, E., Wei L. Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes. 2025. A Network Meta-Analysis. JAMA. Doi: 10.1001/jama.2024.27402	AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly, Roche, Sanofi, Takeda, UCB
2023	7743	Caroline Quach	CHU Sainte-Justine	Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis	Kiely, M., Tadount, F., Lo, E., Sadarangani, M., Wei, S.Q., Rafferty, E., Quach, C. and MacDonald, S.E., 2023. Sex differences in adverse events following seasonal influenza vaccines: a meta-analysis of randomised controlled trials. J Epidemiol Community Health. Doi: 10.1136/jech-2023-220781	Sanofi	4
2022	5933, 5208	Ahmad Abuhelwa	University of South Australia	Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis	Daraghmeh DN, Hopkins AM, King C, Abuhelwa AY, Wechalekar MD, Proudman SM, Sorich MJ, Wiese MD. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford). 2022 Jun 22:keac357. doi : 10.1093/rheumatology/keac357	Roche	2
2026	8427	Ahmad Abuhelwa	University of Sharjah	Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma	Abuhelwa, Ahmad Y., Almansour, Sara A, Al-Shamsi, Humaid O., Abuhelwa, Ziad, Alqudah, Mohammad A. Y., Bustanji, Yasser, Semreen, Mohammad H, Alzoubi, Karem H, Modi, Natansh D, McKinnon, Ross A, Sorich, Michael J. and Hopkins, Ashley M ""Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials"". Scientific Reportsvol. 16, no. 1, Feb. 2026, pp. doi: 0.1038/s41598-026-37464-4	Johnson & Johnson	0
2026	7667	Ashley Hopkins	Flinders University	Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours	Chhetri, Rakchha, Modi, Natansh D, Menz, Bradley D, Cornelisse, Erik, Postma, David, Kuderer, Nicole M, Lyman, Gary H, Swain, Sandra M, Li, Lee X, Abuhelwa, Ahmad Y, McKinnon, Ross A, Vatandoust, Sina, Kichenadasse, Ganessan, Rowland, Andrew, Sorich, Michael J and Hopkins, Ashley M "Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events"". JNCI: Journal of the National Cancer Institutevol. , no. , Feb. 2026, pp. doi: 10.1016/j.cgh.2025.12.020	AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Inc., Lilly, Pfizer Inc., Roche, Sanofi, Takeda	0

Publications by year

Vivli Researcher Spotlight: Investigating the early stroke recurrence rate for people who have experienced minor strokes

January 27, 2025

Ischemic strokes are caused by temporary disruption of blood flow to the brain, and include transient ischemic attacks (TIAs), commonly known as mini-strokes, as well as minor and major strokes. TIAs and minor strokes do not usually have significant long-term effects in and of themselves, but they are important as warning signs of the potential risk of a more significant stroke.

In carrying out research, TIAs are often considered alongside minor strokes, or as a distinct category. However, there has not been significant research to date focusing on minor stroke as a distinct category, particularly with regard to the potential for recurrence in the short term. Developing a better understanding of minor stroke could help improve patient care as well as advance medical knowledge. In a recently completed study, Dr. Andy Lim and colleagues focused on answering the question of whether isolating data relevant to minor stroke could provide useful information about the potential for recurrence.

This meta-analysis involved assessing individual patient data from 45,462 participants in 14 included research studies. The findings indicate that the pooled 90‐day stroke recurrence rate for minor stroke as a distinct category is 8.6%. Furthermore, this rate appears to be declining by 0.60% per year—a trend which seems consistent with those associated with improving outcomes associated with contemporary management of minor stroke and TIA assessed together, as well as for TIA outcomes assessed alone.

Establishing a better understanding of the baseline recurrence rate of minor ischemic stroke can help with comparing new treatments, developing new clinical pathways, and identifying improved methods for managing care. Using the Vivli platform gave the research team access to data from Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack (SOCRATES) trial data, which Dr. Lim described as “an important piece of our meta-analysis puzzle. Without it, we would not be able to complete the picture.”

Vivli webinar: Vivli and RDCA-DAP: Data Platform Partnerships to Promote Rare Disease Data Sharing

January 21, 2025

Julie Wood, Vivli Chief Operating Officer, will join colleagues from Vivli and C-Path for a webinar on Thursday, February 20 at 12:00 pm ET. Julie will present an overview of Vivli’s global data-sharing and analytics platform and how Vivli’s collaboration with RDCA-DAP is advancing data sharing in rare diseases.

In addition to Julie’s presentation, the webinar will also include a panel discussion on platform-to-platform collaborations, strategies for facilitating data sharing, an interactive Q&A session with participants, and more!

View the Recording

Vivli Researcher Spotlight: Examining serological status to better understand treatment response in Rheumatoid Arthritis

July 30, 2024

Rheumatoid arthritis (RA) is an autoimmune disorder, which primarily affects the joints and is characterized by inflammation and pain. RA most commonly affects the hands and wrists, but can also affect other parts of the body. There is currently no cure for RA, but treatment options have improved considerably in recent years with the development of new therapies and treatment strategies.

Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are well established as a standard treatment for RA, used to slow down progression of the disease through broad restriction of the immune systems. Biologic DMARDs (bDMARDs) take a more targeted approach, but it is unclear if it is equally effective across the spectrum of types of RA. In particular, the serological status of people diagnosed with RA may be linked to long-term outcomes. Also, based on differences in associations with genetic and environmental risk factors, seropositive and seronegative disease are presumed to have different underlying pathophysiological mechanisms. However, whether serological status may also affect treatment responses to biological disease-modifying anti-rheumatic drugs (bDMARDs) is not completely clear.

In a recently completed study, Dr. Kaoru Takase-Minegishi and colleagues undertook a meta-analysis based on a systematic literature review including data from 28 randomized controlled trials (RCTs). The research team’s goal was to investigate whether the efficacy of bDMARDs differs in seropositive RA patients (seropositive) compared to those classified as seronegative. Some of the study participants were also receiving csDMARDs, while other were treated bDMARDs exclusively.

The research findings indicate that seropositivity was not associated with a better response to bDMARDs, regardless of whether patients were also receiving csDMARDs. Other outcomes mostly showed no significant difference between the groups, and efficacy was generally comparable between seropositive and seronegative patients for a range of treatment protocols.

Using the Vivli platform enabled the research team to include previously unpublished data, the first opportunity to perform meta-analysis on this complete dataset. Previously unpublished data are included in the Supplementary Material, available online alongside the article recently published in the journal Rheumatology. This research provides a very important additional perspective to the data reported from observational studies thus far, uncovering essential differences.

Read more about Dr. Takase-Minegishi’s research:

Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis (Vivli Research Requests 4922, 3274)
The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials (Abstract, American College of Rheumatology Convergence 2022)
The impact of autoantibodies (RF and ACPA) on the efficacy of biological disease-modifying antirheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials (Annals of the Rheumatic Diseases)
The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials (Rheumatology)

Interested in finding out more about how access to Vivli’s data repository can help advance your research? Find out more about how to search and request data.

Vivli Researcher Spotlight: Rethinking Rheumatoid Arthritis Management: The Dual Target Strategy

February 28, 2024

Rheumatoid arthritis (RA) poses a significant challenge due to its chronic nature and impact on joint health. While treatments have evolved, achieving remission remains elusive for many patients. Using a dataset from the Vivli repository, Dr. Ricardo Ferreira and a team of researchers delved into examining the assessment criteria for remission in RA, shedding light on the limitations of current approaches and proposing a new model—the dual target strategy.

The current standard of treatment is the Treat-to-Target (T2T) approach, which aims for remission or low disease activity. Dr. Ferreira’s team questioned the reliance on a single criterion, the patient global assessment (PGA/PtGA), included in composite measures for determining remission. Their study, drawing from extensive clinical trial data, notably revealed that 19% of patients failed to attain remission based solely on this patient-reported assessment, leading the team to explore a more comprehensive model. In a recent conversation with Vivli, Dr. Ferreira highlighted the research’s key finding: the lack of significant difference in radiographic outcomes between patients classified as “PGA-near-remission” versus those in full remission. This challenges the established understanding of remission incorporating the patient global assessment.

The research team has proposed a dual target strategy, which integrates patient-reported outcomes with objective measures like inflammation status and joint counts to assess inflammatory status and guide immunosuppressive therapy management. The second target (disease impact) would be assessed by informative patient-reported outcome measures, other than PGA. By assigning equal significance to subjective experiences and clinical data, this innovative approach proposes a new benchmark for remission in RA management. Moreover, it has the potential to guide both pharmaceutical and nonpharmacological interventions.

It is anticipated that the dual target strategy has a more patient-centric approach; integrating subjective experiences with objective clinical markers holds promise for improving treatment efficacy and enhancing patient outcomes. With key RA researchers expressing interest in this model, the dual target strategy could significantly change both RA management, and the experience of patients navigating this complex condition. A pragmatic, multicenter, randomized controlled trial is currently being prepared to test this strategy.

Interested in finding out more about how access to Vivli’s data repository can help advance your research? Find out more about how to search and request data.

Vivli Researcher Spotlight: Reusing Data from a Completed Clinical Trial to Inform Guidelines

February 21, 2024

In a recent study led by Dr. Sarah Nevitt, a senior research associate at the University of Liverpool, a team of researchers examined the effectiveness of various antiepileptic drugs (AEDs) used as monotherapy for people experiencing seizures due to epilepsy. Epilepsy, a common neurological disorder, results from abnormal electrical discharges in the brain, causing recurrent seizures. Typically, around 60% to 70% of individuals with epilepsy achieve longer-term remission, often shortly after beginning treatment with antiepileptic drugs.

Dr. Nevitt and her team sought to compare the performance of 12 different AEDs in terms of treatment failure, remission, and occurrence of first seizures among both children and adults with focal onset or generalized tonic‐clonic seizures. They analyzed data from an extensive collection of clinical trials encompassing more than 22,000 participants, incorporating individual patient data from various studies using a network meta-analysis.

The analysis revealed some key insights. Older drugs like phenobarbitone and phenytoin demonstrated better seizure control for both focal and generalized seizures but had poorer long-term retention rates compared to newer medications such as lamotrigine and levetiracetam. Sodium valproate emerged as the top choice for achieving control and remission of generalized tonic‐clonic seizures, although it might not be suitable for everyone, especially people of childbearing age, due to associated risks.

These findings, published in the Cochrane Library, have already influenced the update of UK guidelines in 2022, providing immediate impact on the treatment of individuals newly diagnosed with epilepsy in the UK. In a recent conversation with Vivli, Dr. Nevitt highlighted that these results are guiding the approach to epilepsy treatment, emphasizing the importance of considering both efficacy and potential side effects when selecting appropriate medications for individuals experiencing seizures.

Interested in finding out more about how access to Vivli’s data repository can help advance your research? Find out more about how to search and request data.

There’s more on Vivli than just clinical trial data

September 25, 2023

Did you know there’s more on Vivli than just clinical trial data? The majority of our repository of data comes from clinical trial data, but also includes significant numbers of platform trials, observational studies, and real-world evidence resources.

Vivli’s repository of data from nearly 7,000 research studies is available to search freely. Enter any relevant keyword and you’ll get a listing of pertinent studies of different kinds. Here are some recent search results using common keywords for studies that are not clinical trials:

Observational: 198

Natural history: 26

Platform trial: 420

Explore our How To Guides to learn more about accessing and searching for data with Vivli. If you’d like to take your research further, you can get in touch with us for more information about specific studies or requesting access to data.

News & Events

Tag: IPD

There’s more on Vivli than just clinical trial data